Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationS Brown, M. Miles Braun, Mark H. Greene et al.|Arthritis & Rheumatism|2002Cited by 661
Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and RecommendationsLois B. Travis, Mark H. Greene, Stephen J. Chanock et al.|JNCI Journal of the National Cancer Institute|2006Cited by 344
Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian CancerFrancisco José Cândido dos Reis, Honglin Song, Ellen L. Goode et al.|Clinical Cancer Research|2014Cited by 160
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Kathryn J. Ruddy, Valentina Silvestri, Daniel Barrowdale et al.|Breast Cancer Research|2016Cited by 118
Somatic mutations of KIT in familial testicular germ cell tumoursElizabeth Rapley, Michael R. Stratton, Sarah L. Hockley et al.|British Journal of Cancer|2004Cited by 96